Blog

The U.S. FDA recently approved two CAR T-cell therapies for earlier treatment of adults with multiple myeloma – The Leukemia and Lymphoma Society

Photo taken from The Leukemia and Lymphoma Society/LinkedIn

Apr 20, 2024, 17:31

The U.S. FDA recently approved two CAR T-cell therapies for earlier treatment of adults with multiple myeloma – The Leukemia and Lymphoma Society

The Leukemia and Lymphoma Society shared a post on LinkedIn:

“PROGRESS! The U.S. FDA recently approved two CAR T-cell therapies for earlier treatment of adults with multiple myeloma. Before these approvals, patients had to have received at least four different types of treatment before they were eligible for CAR T-cell therapy.

‘CAR T-cell therapy has come a long way since LLS funded the very earliest studies leading to these landmark treatments,’ says Lee Greenberger, Ph.D., LLS Chief Scientific Officer. ‘These approvals are a big step toward better long-term control of multiple myeloma for more patients.'”

Read further.
Source: The Leukemia and Lymphoma Society/LinkedIn

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”